Lindahl advises LobSor Holding AB in STADA Arzneimittel AG’s acquisition of LobSor Pharmaceuticals AB
LobSor was founded 2012 in Uppsala, Sweden. LobSor provides of an innovative therapy system used for treating late-stage Parkinson’s disease. LobSor Pharma has developed a new gel formulation of a fixed triple combination of levodopa, carbidopa and entacapone, which is infused through a modern pump technology for continuous intestinal use. The therapy has been launched in Sweden, Denmark, Norway and Finland, and STADA is currently submitting approval applications to launch the therapy in a number of major European markets.
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. The majority owners are Bain Capital and Cinven.
Lindahl’s core deal team consists of Mikael Smedeby (Life Science/Corporate Finance), Hugo Norlén (Life Science/IP), Erika Svensson (Life Science/Corporate Finance), Therese Norenäs (Tax) and Disa Almqvist (Corporate Finance).